The Cancer-Fighting Journey of Ribociclib (Kisqali®): A Powerful Breast Cancer Drug

Every cancer drug comes equipped with unique tools to combat its formidable enemy—cancer cells. Each drug’s approval represents numerous victories in clinical trials before appearing in hospitals. In the busy world of pharmaceuticals, scientists are modern-day wizards, and their labs are castles where potential cancer-fighting spells are created.

A Weapon Against Breast Cancer—Ribociclib

Ribociclib, often nicknamed "Ribo," was not created overnight. New drugs result from years of research and sometimes pure luck. Scientists at Novartis developed Ribo, a CDK4/6 inhibitor, to target a particularly elusive adversary—breast cancer. CDK4/6 is a protein in the cell nucleus that promotes cancer cell replication.

Like all heroes, Ribo had to endure clinical trials, akin to a magical game with various stages (Phase I, II, and III trials). Throughout its journey, Ribo allied with letrozole (Femara®) and fulvestrant (Faslodex®) to combat breast cancer. Their epic battles are documented in the New England Journal of Medicine. After many years, the FDA granted Ribo the honor to join the real-world fight against breast cancer.

Ribociclib and Breast Cancer Treatment

Ribociclib is a small molecule, often called a "magic bullet." HR-positive, HER2-negative breast cancer is the most common subtype, accounting for 70-75% of all cases. Most of these cases are diagnosed early (Stages I to III) and aim for a cure. Typically, early-stage HR-positive, HER2-negative breast cancer is treated with surgery, possibly followed by radiation or chemotherapy, and then 5-10 years of adjuvant endocrine (anti-hormone) therapy to improve prognosis. However, 27-37% of Stage II and 46-57% of Stage III patients may experience recurrence within 20 years.

Trials evaluating three CDK4/6 inhibitors—ribociclib (Kisqali®), palbociclib (Ibrance®), and abemaciclib (Verzenio®)—showed significant improvements in disease-free survival for HR-positive, HER2-negative advanced breast cancer. However, results varied for early breast cancer. In the PENELOPE-B and PALLAS trials, palbociclib plus endocrine therapy did not show significant benefits, whereas the monarchE trial demonstrated significant disease-free survival benefits with abemaciclib. These findings led to international health authorities approving abemaciclib for high-risk HR-positive, HER2-negative early breast cancer with positive lymph nodes.

Ribociclib Proven to Reduce Breast Cancer Recurrence

Having established its efficacy in advanced breast cancer, Ribociclib aimed to prove its worth in early-stage HR-positive, HER2-negative breast cancer. A Phase II/III trial involving three weeks of ribociclib followed by one week off, combined with daily letrozole (2.5 mg) or anastrozole (1 mg) for three years, was compared to anti-hormone therapy alone. Published in the New England Journal of Medicine on March 20, 2024, the trial showed a 90.4% disease-free survival rate with ribociclib versus 87.1% with only anti-hormone therapy, indicating a 25% reduction in recurrence risk. Common side effects included neutropenia, joint pain, and liver-related events such as elevated liver enzymes. These results mark a significant advancement in treating breast cancer as a chronic disease.